HSP

Hospira Inc. (HSP) said Tuesday that its drug Docetaxel, a generic version of the Sanofi-Aventis SA (SNY, SAN.FR) cancer drug Taxotere and an important growth driver for Hospira, hasn't garnered final Food and Drug Administration approval as soon as hoped because the agency had product-label questions.

The generic drug has tentative approval, and on Nov. 15 Hospira said in a press release that the next item needed--the FDA's approval for the final drug label--was expected within 10 business days. But the FDA requested amendments to that labeling, which the company has submitted for approval, Hospira said Tuesday.

"While Hospira cannot predict the timing for conversion of its tentatively approved Docetaxel to final approval, Hospira continues to work closely with the FDA to expedite this matter," the company said in a filing with the Securities and Exchange Commission.

Hospira spokesman Dan Rosenberg said the FDA asked the company to rework the label, the product inserts and customer materials, but there isn't an issue with the drug itself. Hospira already sells Docetaxel outside the U.S.

JPMorgan analysts said this new development likely is "a more minor delay with approval still a matter of when, not if." But if U.S. approval for Hospira's "key growth driver for 2011" doesn't come this year as JPMorgan forecasted, the delay could knock about 10 cents off the firm's 2010 per-share earnings estimate of $3.55, analysts said.

Hospira said in October that its adjusted $3.40 to $3.45 per share earnings guidance for this year didn't include any contribution from Docetaxel or another generic cancer drug called Gemcitabine, although the company saw a chance both could launch domestically in November. It announced the launch of Gemcitabine--a generic version of the Eli Lilly & Co. (LLY) chemotherapy drug Gemzar--on November 15.

Hospira shares recently traded down 0.6% to $55.96, but are up 9.7% on the year.

-By Jon Kamp, Dow Jones Newswires; 617-654-6728; jon.kamp@dowjones.com

Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024

Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024